Full Breakdown
Gut Bacteria Convert Pomegranate Polyphenols into Cardioprotective Urolithin A
4/28/2026, 12:51:15 AM
Core Study: Microbial Metabolism of Pomegranate Compounds Reduces Atherosclerosis in Mice
Cardiff University scientists administered urolithin A, a metabolite produced by gut microbes from pomegranate polyphenol punicalagin, to LDL-receptor-deficient mice on a high-fat diet for twelve weeks. Treated animals showed smaller arterial plaques and reduced inflammatory cell infiltration.
Metabolic Pathway: From Punicalagin to Urolithin A
Punicalagin is poorly absorbed; gut bacteria hydrolyze it to ellagic acid and then to urolithins, chiefly urolithin A, which enters circulation and can interact with vascular cells.
Lead Researchers and Publication
The work was led by Professor Dipak Ramji, Professor of Cardiovascular Science at Cardiff University, with co-authors Sulaiman Alalawi, Daniah Rifqi, Alaa Alhamadi and others. Results appeared in *Antioxidants* (19 April 2026).
Preclinical Findings
In vitro, urolithin A lowered oxidative stress, inflammatory gene expression, immune-cell migration and macrophage cholesterol uptake in endothelial cells. In vivo, treated mice displayed smaller plaques, fewer inflammatory cells, and higher smooth-muscle cell and collagen content, indicating stability. Systemic analysis showed fewer inflammatory monocytes and granulocytes and more short-chain fatty acids. RNA-seq showed modulation of hundreds of genes, suppressing atherogenic pathways and activating antioxidant routes.
Clinical Implications
If similar effects occur in humans, urolithin A could complement heart-disease therapies by dampening inflammation and stabilizing plaques without changing blood cholesterol. The findings also imply that gut-microbiome composition may dictate benefit from pomegranate-rich diets.
Official Researcher Summary
The authors say the cardioprotective effects stem from microbial metabolites, not the fruit itself, indicating a novel mechanism. They note benefits occurred without cholesterol reduction, suggesting an anti-inflammatory, plaque-stabilizing pathway. They acknowledge gut-microbiota variability may influence urolithin A production, highlighting a need for personalized approaches.
Limitations and Knowledge Gaps
The study was limited to a murine model; human trials are required to confirm efficacy and safety. Differences in individuals’ gut microbiomes may limit universal applicability. No data on long-term outcomes or optimal dosing were provided.
Verbatim Quotes
- “Our findings show that the real biological effects come from what gut bacteria make from pomegranate compounds, rather than from the compounds in the fruit itself,” — Professor Dipak Ramji, Cardiff University
- “What was striking is that these benefits occurred without lowering blood cholesterol levels,” — Professor Dipak Ramji
- “These results help explain why diets rich in fruits like pomegranates are associated with cardiovascular benefits, but also why responses can vary between individuals,” — Professor Dipak Ramji
- “This study opens the door to the use of urolithin A and microbiome-driven strategies for cardiovascular disease prevention,” — Professor Dipak Ramji
Upcoming Human Studies
The team plans to initiate clinical trials to evaluate urolithin A’s safety, dosing, and efficacy in patients with atherosclerosis. Parallel work will map microbiome profiles that predict robust urolithin A production, potentially guiding personalized dietary or probiotic interventions.
